3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
3
Head & Neck
3
Genitourinary
3
Dermatologic
3
Gastrointestinal
2
Lymphoid
1
Gynecologic
1
Breast
1
Conditions
Breast Neoplasms
3
Triple Negative Breast Neoplasms
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Melanoma
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
44
Cyclophosphamide
21
Nivolumab
18
fludarabine
10
durvalumab
8
Paclitaxel
8
Magnetic Resonance Spectroscopy
8
Interleukin-2
8
Docetaxel
8
aldesleukin
7
Radiosurgery
7
Ipilimumab
7
spartalizumab
6
poly ICLC
6
fludarabine phosphate
6
atezolizumab
6
Specimen Handling
6
Radiotherapy
6
Carboplatin
6
cemiplimab
5
Drug Therapy
5
Cisplatin
5
Biopsy
5
Temozolomide
4
Immune Checkpoint Inhibitors
4
tremelimumab
3
technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran
3
pazopanib
3
avelumab
3
Trastuzumab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Melanoma
×
utomilumab
×
Breast
×
Clear all
NCT02554812
2024-07-30
JAVELIN Medley
Pfizer
Phase 1/2
Terminated
409 enrolled
108 charts